Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Nov 19;300(2):H605–H616. doi: 10.1152/ajpheart.00824.2010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 the American Physiological Society

This document may be redistributed and reused, subject to www.the-aps.org/publications/journals/funding_addendum_policy.htm.

PMC Copyright notice

Fig. 2. — A: typical BEG traces from RV apex or RVOT of wild-type (WT) and Scn5a+/− hearts, either before drug or after treatment with either flecainide or quinidine. The arrows denote stimulus artifacts, the first in each trace from an S1 stimulus and the second from an S2 stimulus. B–D: comparison of conduction curves from the base of the RV in a WT heart and in an Scn5a+/− heart (B), and at the base of an Scn5a+/− heart before and after flecainide (C) or quinidine (D). E: electrogram duration (EGD) ratios calculated from WT and Scn5a+/− hearts in 7 positions across the heart, before and after the addition of flecainide or quinidine.